

MEDICAID POLICY CHANGE

IMMINENT PERIL JUSTIFICATION

April 26, 2023

SUSPENDING AGENTS

POLICY CHANGE:

Removal of the drug Alpha Hydroxyprogesterone Caproate from the MCO Manual.

JUSTIFICATION:

On April 6, 2023, the Food and Drug Administration (FDA) withdrew approval of the drug Makena, or Alpha Hydroxyprogesterone Caproate, and its generics. Approval of this drug has been withdrawn because the drugs are no longer shown to be effective and the benefits do not outweigh the risks for the indication for which they were approved. LDH finds that the imminent peril to the public health requires immediate adoption of the proposed policy change, and will therefore bypass the 45-day public notice period.

EFFECTIVE DATE:

April 6, 2023